Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.44 |
| ▸ | BRAF | P15056 | 9/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5055062 | 0.92 | NPC1 (0.39) | MAPK14BRAFNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5052138 | 0.91 | MAPK14 (0.55) | MAPK14BRAFMAPK13KDR | |
| SCHEMBL5060332 | 0.90 | NPC1 (0.37) | MAPK14BRAFNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5055302 | 0.89 | MAPK14 (0.44) | MAPK14BRAFMAPK13NPC1RAB9A | |
| SCHEMBL5052191 | 0.87 | RAF1 (0.49) | MAPK14BRAFMAPK13KDR | |
| SCHEMBL5054970 | 0.86 | MAPK14 (0.43) | MAPK14BRAFMAPK13KDRP2RX3 | |
| SCHEMBL5055197 | 0.85 | MAPK14 (0.44) | MAPK14BRAFMAPK13KDRP2RX3 | |
| SCHEMBL5056399 | 0.85 | MAPK14 (0.44) | MAPK14BRAFMAPK13KDRP2RX3 | |
| SCHEMBL5062035 | 0.84 | ABL1 (0.46) | MAPK14BRAFMAPK13NPC1KDR | |
| SCHEMBL5062706 | 0.84 | MAPK14 (0.46) | MAPK14BRAFMAPK13KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | MAPK14 100/4885BRAF 2/4885MAPK13 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.